Is Zanubrutinib available in China?

Zanubrutinib (Zanubrutinib) is a second-generation BTK inhibitor that was discovered in 2012 by the Chinese companyBeiGene (BeiGene). A first-in-human study of the drug in patients with B-cell malignancies began in Australia in 2014, with expansion cohorts conducted in the United States and other countries in 2015. According to preliminary efficacy data, it was mainly based on a single-arm phase II trial involving Chinese patients with relapsed and/or refractory mantle cell lymphoma (R/R MCL). It was approved for marketing by the National Medical Products Administration in June 2020 under the trade name of Baiyueze.